vs
Emergent BioSolutions Inc.（EBS）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是Emergent BioSolutions Inc.的1.5倍（$225.0M vs $148.7M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $26.2M），过去两年GIBRALTAR INDUSTRIES, INC.的营收复合增速更高（-12.3% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
EBS vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.5倍
$148.7M
营收增速更快
ROCK
高出48.6%
-23.6%
自由现金流更多
EBS
多$47.6M
$26.2M
两年增速更快
ROCK
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $225.0M |
| 净利润 | $-54.6M | — |
| 毛利率 | 42.9% | 25.3% |
| 营业利润率 | -18.8% | 7.9% |
| 净利率 | -36.7% | — |
| 营收同比 | -23.6% | 24.9% |
| 净利润同比 | -74.4% | — |
| 每股收益（稀释后） | $-0.95 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSROCK
| Q4 25 | $148.7M | $225.0M | ||
| Q3 25 | $231.1M | $310.9M | ||
| Q2 25 | $140.9M | $309.5M | ||
| Q1 25 | $222.2M | $290.0M | ||
| Q4 24 | $194.7M | $180.1M | ||
| Q3 24 | $293.8M | $277.1M | ||
| Q2 24 | $254.7M | $273.6M | ||
| Q1 24 | $300.4M | $292.5M |
净利润EBSROCK
| Q4 25 | $-54.6M | — | ||
| Q3 25 | $51.2M | $-89.1M | ||
| Q2 25 | $-12.0M | $26.0M | ||
| Q1 25 | $68.0M | $21.1M | ||
| Q4 24 | $-31.3M | — | ||
| Q3 24 | $114.8M | $34.0M | ||
| Q2 24 | $-283.1M | $32.2M | ||
| Q1 24 | $9.0M | $24.9M |
毛利率EBSROCK
| Q4 25 | 42.9% | 25.3% | ||
| Q3 25 | 62.8% | 26.6% | ||
| Q2 25 | 52.5% | 28.4% | ||
| Q1 25 | 60.2% | 26.8% | ||
| Q4 24 | 39.4% | 29.0% | ||
| Q3 24 | 54.9% | 29.4% | ||
| Q2 24 | -18.8% | 30.5% | ||
| Q1 24 | 49.2% | 28.9% |
营业利润率EBSROCK
| Q4 25 | -18.8% | 7.9% | ||
| Q3 25 | 33.1% | 12.8% | ||
| Q2 25 | 1.1% | 12.8% | ||
| Q1 25 | 22.5% | 8.8% | ||
| Q4 24 | -4.9% | 13.3% | ||
| Q3 24 | 22.0% | 15.6% | ||
| Q2 24 | -79.9% | 14.9% | ||
| Q1 24 | 13.2% | 10.8% |
净利率EBSROCK
| Q4 25 | -36.7% | — | ||
| Q3 25 | 22.2% | -28.6% | ||
| Q2 25 | -8.5% | 8.4% | ||
| Q1 25 | 30.6% | 7.3% | ||
| Q4 24 | -16.1% | — | ||
| Q3 24 | 39.1% | 12.3% | ||
| Q2 24 | -111.2% | 11.8% | ||
| Q1 24 | 3.0% | 8.5% |
每股收益（稀释后）EBSROCK
| Q4 25 | $-0.95 | — | ||
| Q3 25 | $0.91 | $-2.98 | ||
| Q2 25 | $-0.22 | $0.87 | ||
| Q1 25 | $1.19 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $2.06 | $1.11 | ||
| Q2 24 | $-5.38 | $1.05 | ||
| Q1 24 | $0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $115.7M |
| 总债务越低越好 | $589.7M | $0 |
| 股东权益账面价值 | $522.6M | $950.4M |
| 总资产 | $1.3B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.13× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资EBSROCK
| Q4 25 | $205.4M | $115.7M | ||
| Q3 25 | $245.5M | $89.4M | ||
| Q2 25 | $267.3M | $43.3M | ||
| Q1 25 | $149.1M | $25.1M | ||
| Q4 24 | $99.5M | $269.5M | ||
| Q3 24 | $149.9M | $228.9M | ||
| Q2 24 | $69.7M | $179.1M | ||
| Q1 24 | $78.5M | $146.7M |
总债务EBSROCK
| Q4 25 | $589.7M | $0 | ||
| Q3 25 | $693.1M | $0 | ||
| Q2 25 | $700.0M | $0 | ||
| Q1 25 | $700.0M | $0 | ||
| Q4 24 | $700.0M | $0 | ||
| Q3 24 | $700.8M | $0 | ||
| Q2 24 | $863.8M | $0 | ||
| Q1 24 | $909.2M | $0 |
股东权益EBSROCK
| Q4 25 | $522.6M | $950.4M | ||
| Q3 25 | $582.5M | $951.8M | ||
| Q2 25 | $536.2M | $1.0B | ||
| Q1 25 | $552.7M | $1.0B | ||
| Q4 24 | $482.8M | $1.0B | ||
| Q3 24 | $508.4M | $1.0B | ||
| Q2 24 | $386.3M | $975.7M | ||
| Q1 24 | $663.9M | $940.2M |
总资产EBSROCK
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $1.4B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B | ||
| Q1 24 | $1.8B | $1.3B |
负债/权益比EBSROCK
| Q4 25 | 1.13× | 0.00× | ||
| Q3 25 | 1.19× | 0.00× | ||
| Q2 25 | 1.31× | 0.00× | ||
| Q1 25 | 1.27× | 0.00× | ||
| Q4 24 | 1.45× | 0.00× | ||
| Q3 24 | 1.38× | 0.00× | ||
| Q2 24 | 2.24× | 0.00× | ||
| Q1 24 | 1.37× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $26.2M |
| 自由现金流率自由现金流/营收 | 49.6% | 11.7% |
| 资本支出强度资本支出/营收 | 2.6% | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $120.6M |
8季度趋势，按日历期对齐
经营现金流EBSROCK
| Q4 25 | $77.7M | $35.5M | ||
| Q3 25 | $-2.3M | $73.0M | ||
| Q2 25 | $106.4M | $44.9M | ||
| Q1 25 | $-11.2M | $13.7M | ||
| Q4 24 | $-79.9M | $19.9M | ||
| Q3 24 | $153.7M | $64.7M | ||
| Q2 24 | $47.5M | $36.5M | ||
| Q1 24 | $-62.6M | $53.2M |
自由现金流EBSROCK
| Q4 25 | $73.8M | $26.2M | ||
| Q3 25 | $-5.7M | $64.8M | ||
| Q2 25 | $103.5M | $27.3M | ||
| Q1 25 | $-14.8M | $2.3M | ||
| Q4 24 | $-81.6M | $14.1M | ||
| Q3 24 | $147.9M | $60.5M | ||
| Q2 24 | $42.9M | $33.5M | ||
| Q1 24 | $-73.4M | $48.8M |
自由现金流率EBSROCK
| Q4 25 | 49.6% | 11.7% | ||
| Q3 25 | -2.5% | 20.8% | ||
| Q2 25 | 73.5% | 8.8% | ||
| Q1 25 | -6.7% | 0.8% | ||
| Q4 24 | -41.9% | 7.8% | ||
| Q3 24 | 50.3% | 21.8% | ||
| Q2 24 | 16.8% | 12.2% | ||
| Q1 24 | -24.4% | 16.7% |
资本支出强度EBSROCK
| Q4 25 | 2.6% | 4.1% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 2.1% | 5.7% | ||
| Q1 25 | 1.6% | 3.9% | ||
| Q4 24 | 0.9% | 3.3% | ||
| Q3 24 | 2.0% | 1.5% | ||
| Q2 24 | 1.8% | 1.1% | ||
| Q1 24 | 3.6% | 1.5% |
现金转化率EBSROCK
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | -0.16× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | 1.90× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | -6.96× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
